## Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

## M.8522 - Avantor / VWR

## **SECTION 1.2**

## **Description of the concentration**

The Commission has received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the "EUMR"). On 15 September 2017, Avantor, Inc. (Avantor) notified its intention to acquire indirect sole control of VWR Corporation (VWR) by way of purchase of shares. The transaction is a concentration within the meaning of Article 3(1) of the EUMR. Avantor is controlled by funds affiliated with New Mountain Capital, LLC (New Mountain).

The areas of activities of the undertakings concerned by the notified concentration are as follows:

- a) **Avantor** global supplier of ultra-high purity materials for the life sciences and advanced technology sectors including the biotechnology, medical device, diagnostics, aerospace and defence, and semiconductor industries.
- b) New Mountain private equity investment firm.
- c) **VWR** global independent distributor of laboratory products and services solutions to laboratory and production customers.